BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19076159)

  • 1. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
    Suzuki K; Doki K; Homma M; Tamaki H; Hori S; Ohtani H; Sawada Y; Kohda Y
    Br J Clin Pharmacol; 2009 Jan; 67(1):44-9. PubMed ID: 19076159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
    Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
    Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis.
    Wang X; Song Y; Wang J; He J; Liu R; Li X; Huang H; Zhang J
    Int J Clin Pharm; 2020 Feb; 42(1):23-30. PubMed ID: 31916121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors.
    Reeves DJ; Moore ES; Bascom D; Rensing B
    Br J Clin Pharmacol; 2014 Sep; 78(3):565-71. PubMed ID: 24646036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats.
    Ueda H; Narumi K; Sato Y; Furugen A; Kobayashi M; Iseki K
    Pharmacol Rep; 2020 Oct; 72(5):1426-1432. PubMed ID: 32671657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3.
    Chioukh R; Noel-Hudson MS; Ribes S; Fournier N; Becquemont L; Verstuyft C
    Drug Metab Dispos; 2014 Dec; 42(12):2041-8. PubMed ID: 25239859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors.
    Santucci R; Levêque D; Lescoute A; Kemmel V; Herbrecht R
    Anticancer Res; 2010 Sep; 30(9):3807-10. PubMed ID: 20944174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
    Ranchon F; Vantard N; Henin E; Bachy E; Sarkozy C; Karlin L; Bouafia-Sauvy F; Gouraud A; Schwiertz V; Bourbon E; Baudouin A; Caffin AG; Vial T; Salles G; Rioufol C
    Hematol Oncol; 2018 Apr; 36(2):399-406. PubMed ID: 28983943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.
    Huang C; Xia F; Xue L; Liu L; Bian Y; Jin Z; Miao L
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):433-441. PubMed ID: 31691080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.
    Ikemura K; Hiramatsu SI; Shinogi Y; Nakatani Y; Tawara I; Iwamoto T; Katayama N; Okuda M
    Sci Rep; 2019 Dec; 9(1):20359. PubMed ID: 31889141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin.
    Boerrigter E; Crul M
    Ann Pharm Fr; 2017 Sep; 75(5):344-348. PubMed ID: 28705331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo.
    Vlaming ML; van Esch A; Pala Z; Wagenaar E; van de Wetering K; van Tellingen O; Schinkel AH
    Mol Cancer Ther; 2009 Dec; 8(12):3350-9. PubMed ID: 19996279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
    Volk EL; Schneider E
    Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
    El Mesallamy HO; Rashed WM; Hamdy NM; Hamdy N
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1359-65. PubMed ID: 24718721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
    Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R
    Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
    Rhee MS; Schneider E
    Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.
    Mutsaers HA; van den Heuvel LP; Ringens LH; Dankers AC; Russel FG; Wetzels JF; Hoenderop JG; Masereeuw R
    PLoS One; 2011 Apr; 6(4):e18438. PubMed ID: 21483698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation into the impact of proton pump inhibitors on sertraline transport across the blood-brain barrier.
    Xiao Y; Xu W; Niu D; Quan Z; Wang L
    Eur J Pharm Sci; 2024 Mar; 194():106653. PubMed ID: 38006986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.